top of page
Out Team
Our Research
STARLIGHT Initiative
Project PRESCIENT
PMAC Catalog

Welcome!

The Cancer Discovery Hub (CDH) is a one-stop pan-omics diagnostic and research core laboratory housed at the National Cancer Centre Singapore. We specialise in state-of-the-art research-grade technologies and provide expert support to investigators on all cancer related projects.

Home: Welcome

Latest news

Key events and achievements

  • 01 Nov 2023: Poster Presentation, CTOS Annual Meeting, Dublin (Elizabeth Lee)

    • Tumor-infiltrating mast cells in angiosarcomas correlate with adverse clinical phenotypes and immuno-oncology pathways

  • 15 Sep 2023 : MOU and RCA signed with Agilent Technologies, BioSyngen, BGI Research and MGI Tech

  • 14 June 2023 : Poster Presentation, ICML Lugano, Switzerland

    • Brincidofovir induces potent anti-tumor activity in MYC-driven Natural Killer/T-cell Lymphoma with loss of transcriptional repressor TLE1

  • 14 April 2023 : Poster Presentation, AACR Annual Meeting, Florida, USA (Bavani Kannan)

    • ​​​​Single cell landscape of Multicentric Castleman Disease in Identical twins

  • 20 Mar 2023 : ESMO Merit Award, ESMO Sarcoma and Rare Cancers Congress, Lugano, Switzerland

    • Transcriptomic and enhancer landscape profiling identify Src-family kinase LYN as a candidate therapeutic target in human angiosarcoma​

    • Multi-omic profiling and real time ex vivo modelling of imatinib-resistant dermatofibrosarcoma protuberans with fibrosarcomatous transformation

  • 18 Mar 2023 : Co-organized Singapore Lymphoma Scientific Symposium 2023

  • 12 Dec 2022 : Oral abstract, ASH Annual Meeting, New Orleans, USA

    • Therapeutic Repurposing of Brincidofovir in Natural Killer/T-cell Lymphoma Reveals Potent Induction of Replication Stress, STING Pathway Activation and Immunogenic Cell Death

  • 09 Dec 2022 : Invited presentation, Stem Cell Society Singapore (SCSS) Symposium (Nimmi Baby)

  • 17 Nov 2022 : Oral paper, CTOS Annual Meeting, Vancouver, Canada (Jing Yi Lee)

    • Spatial transcriptomics reveal topological immune landscapes of Asian head and neck angiosarcoma​

  • 19 Aug 2022 : Invited speech, 6th International BRCA Forum, Singapore

    • Precision Oncology: The Time is Now !

  • 19 Aug 2022 : Collaborative research agreement with Scinnohub Pharmaceutical

  • 19 Aug 2022 : Collaborative research agreement with MGI Tech

  • 04 Aug 2022 : Collaborative research agreement with Twist Bioscience

  • 16 Jun 2022 : Best Oral Presentation, International Congress of the Asian Oncology Society (AOS 2022), South Korea

    • ctDNA mutations in progressive gastrointestinal stromal tumors identify drug resistance biomarkers and uncover potential therapeutic strategies (Tun Kiat Ko)

  • 12 Apr 2022 : Invited Oral Presentation at Major Symposium, AACR Annual Meeting, New Orleans, USA

    • Identification and characterization of human angiosarcoma subtypes through multi-omic multi-dimensional profiling

  • 22 Feb 2022 : Publication on circulating tumor DNA mutations in progressive gastrointestinal stromal tumors, Frontiers in Oncology

  • 17 Feb 2022 : Travel Award for Poster abstract at Japanese Society of Medical Oncology Annual Meeting, Japan

    • Dissecting Intratumoral Heterogeneity of Sarcomatoid RCC Arising from Autosomal Dominant Polycystic Kidney Disease (Elizabeth Lee)

  • 12 Jan 2022 : Commercial launch of the UNITED NGS Assay (Lucence) for Asian prevalent cancers at the NCCS

  • 21 Oct 2021 : Collaborative research agreement with STEMCELL Technologies

  • 01 Sep 2021 : Collaborative research agreement with SymBio Pharmaceuticals on EBV-positive lymphomas

  • 01 Sep 2021 : Official launch of Cancer Discovery Hub!

Home: Services

Start a project consultation with us

Featured Publications

Scientific publications supported by the Cancer Discovery Hub

Integrative multiomics enhancer activity profiling identifies therapeutic vulnerabilities in cholangiocarcinoma of different etiologies
Gut. 2023

Nov, 2023

Objectives: Cholangiocarcinoma (CCA) is a heterogeneous malignancy with high mortality and dismal prognosis, and an urgent clinical need for new therapies. Knowledge of the CCA epigenome is largely limited to aberrant DNA methylation. Dysregulation of enhancer activities has been identified to affect carcinogenesis and leveraged for new therapies but is uninvestigated in CCA. Our aim is to identify potential therapeutic targets in different subtypes of CCA through enhancer profiling.

Design: Integrative multiomics enhancer activity profiling of diverse CCA was performed. A panel of diverse CCA cell lines, patient-derived and cell line-derived xenografts were used to study identified enriched pathways and vulnerabilities. NanoString, multiplex immunohistochemistry staining and single-cell spatial transcriptomics were used to explore the immunogenicity of diverse CCA.

Results: We identified three distinct groups, associated with different etiologies and unique pathways. Drug inhibitors of identified pathways reduced tumour growth in in vitro and in vivo models. The first group (ESTRO), with mostly fluke-positive CCAs, displayed activation in estrogen signalling and were sensitive to MTOR inhibitors. Another group (OXPHO), with mostly BAP1 and IDH-mutant CCAs, displayed activated oxidative phosphorylation pathways, and were sensitive to oxidative phosphorylation inhibitors. Immune-related pathways were activated in the final group (IMMUN), made up of an immunogenic CCA subtype and CCA with aristolochic acid (AA) mutational signatures. Intratumour differences in AA mutation load were correlated to intratumour variation of different immune cell populations.

Conclusion: Our study elucidates the mechanisms underlying enhancer dysregulation and deepens understanding of different tumourigenesis processes in distinct CCA subtypes, with potential significant therapeutics and clinical benefits.

Contact us

  • LinkedIn
  • Facebook
  • Instagram

Thanks for submitting!

Home: Contact
bottom of page